Long-term outcome of molecular subgroups of GIST patients treated with standard-dose imatinib in the BFR14 trial of the French Sarcoma Group.

[1]  J. Blay,et al.  Tumor Genotype Is an Independent Prognostic Factor in Primary Gastrointestinal Stromal Tumors of Gastric Origin: A European Multicenter Analysis Based on ConticaGIST , 2014, Clinical Cancer Research.

[2]  J. Blay,et al.  Effects of endoplasmic reticulum stressors on maturation and signaling of hemizygous and heterozygous wild‐type and mutant forms of KIT , 2013, Molecular oncology.

[3]  J. Blay,et al.  Gene Expression Patterns of Hemizygous and Heterozygous KIT Mutations Suggest Distinct Oncogenic Pathways: A Study in NIH3T3 Cell Lines and GIST Samples , 2013, PloS one.

[4]  J. Blay,et al.  Influence of imatinib interruption and rechallenge on the residual disease in patients with advanced GIST: results of the BFR14 prospective French Sarcoma Group randomised, phase III trial. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  F. Bertucci,et al.  Who are the long responders to imatinib (IM) in patients with advanced GIST? Results of the BFR14 prospective French Sarcoma Group randomized phase III trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  G. Demetri,et al.  Follow-up results after 9 years (yrs) of the ongoing, phase II B2222 trial of imatinib mesylate (IM) in patients (pts) with metastatic or unresectable KIT+ gastrointestinal stromal tumors (GIST). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  J. Coindre,et al.  A quality control program for mutation detection in KIT and PDGFRA in gastrointestinal stromal tumours , 2011, Journal of Gastroenterology.

[8]  J. Blay,et al.  Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial. , 2010, The Lancet. Oncology.

[9]  J. Carles,et al.  Prognostic time dependence of deletions affecting codons 557 and/or 558 of KIT gene for relapse-free survival (RFS) in localized GIST: a Spanish Group for Sarcoma Research (GEIS) Study. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  J. Blay,et al.  Risk of relapse with imatinib (IM) discontinuation at 5 years in advanced GIST patients: Results of the prospective BFR14 randomized phase III study comparing interruption versus continuation of IM at 5 years of treatment: A French Sarcoma Group Study. , 2010 .

[11]  J. Blay,et al.  Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. , 2009, Cancer research.

[12]  J. Blay,et al.  Prognosis and predictive value of KIT exon 11 deletion in GISTs , 2009, British Journal of Cancer.

[13]  K. Owzar,et al.  Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  N. Pandis,et al.  KIT exon 11 codon 557/558 deletion/insertion mutations define a subset of gastrointestinal stromal tumors with malignant potential. , 2008, World journal of gastroenterology.

[15]  J. Fletcher,et al.  Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  J. Crowley,et al.  Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  C. Antonescu,et al.  Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST) , 2008, Cancer.

[18]  J. Blay,et al.  Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  J. Blay,et al.  KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. , 2006, European journal of cancer.

[20]  E. Glatstein,et al.  Progression-free Survival in Gastrointestinal Stromal Tumours With High-dose Imatinib: Randomised Trial , 2006 .

[21]  A. Llombart‐Bosch,et al.  Deletions affecting codons 557-558 of the c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors: a study by the Spanish Group for Sarcoma Research (GEIS). , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  M. van Glabbeke,et al.  Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. , 2004, European journal of cancer.

[23]  A. D. Van den Abbeele,et al.  Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  E. Wardelmann,et al.  Deletion of Trp‐557 and Lys‐558 in the juxtamembrane domain of the c‐kit protooncogene is associated with metastatic behavior of gastrointestinal stromal tumors , 2003, International journal of cancer.

[25]  P. Terrier,et al.  Length Analysis of Polymerase Chain Reaction Products: A Sensitive and Reliable Technique for the Detection of Mutations in KIT Exon 11 in Gastrointestinal Stromal Tumors , 2002, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[26]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[27]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.